Denmark: IO Biotech raises US$100m to advance development of lead

IO Biotech, headquartered in Denmark, priced the IPO of 7,150,000 shares of its common stock at a US$14.00 per share on Nasdaq, to raise total gross proceeds of around US$100m. The underwriters have a 30-day option to purchase up to an additional 1,072,500 shares. IO Biotech is advancing in clinical studies its lead immuno-oncology candidate,…

You must be a HMI Subscriber to view this content.

Subscribe Now »